Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ixaka
Deal Size : Undisclosed
Deal Type : Collaboration
Ixaka and SomaLogic Enter Research Collaboration to Develop Bispecific Agents for Oncology
Details : The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer® reagents previously identified and screened by SomaLogic as potential candidates for combination with Ixaka’s anti-CD3 aptamers.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 29, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ixaka
Deal Size : Undisclosed
Deal Type : Collaboration